L
1.71
-0.07 (-3.93%)
| Previous Close | 1.78 |
| Volume | 34,442 |
| Price / Sales | 3.68 |
| Price / Book | 0.550 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,359.84% |
| Diluted EPS (TTM) | -1.35 |
| Quarterly Revenue Growth (YOY) | -30.50% |
| Total Debt/Equity (MRQ) | 7.55% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | -15.48 M |
| Levered Free Cash Flow (TTM) | -10.69 M |
| Return on Assets (TTM) | -72.08% |
| Return on Equity (TTM) | -167.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Longeveron Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.24 |
Select this tab to load the latest available analysis.
|
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.45% |
| % Held by Institutions | 8.78% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |